Fate Therapeutics, Inc.
(NASDAQ : FATE)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
BIIBBiogen, Inc.
-2.36%275.241.4%$809.20m
AMGNAmgen, Inc.
-0.56%217.001.3%$492.24m
CELGCelgene Corp.
-0.47%109.891.3%$454.55m
GILDGilead Sciences, Inc.
0.02%63.341.0%$379.12m
ILMNIllumina, Inc.
0.02%298.293.5%$303.29m
VRTXVertex Pharmaceuticals, Inc.
-1.24%204.531.9%$296.06m
REGNRegeneron Pharmaceuticals, Inc.
-2.36%340.092.6%$258.39m
EXASEXACT Sciences Corp.
2.09%79.8924.0%$198.96m
ALXNAlexion Pharmaceuticals, Inc.
-1.62%105.402.0%$180.23m
SGENSeattle Genetics, Inc.
-0.18%112.016.1%$131.31m
BMRNBioMarin Pharmaceutical, Inc.
-0.73%75.584.3%$115.39m
SRPTSarepta Therapeutics, Inc.
-3.38%97.5914.6%$111.53m
AAgilent Technologies, Inc.
-0.35%76.891.6%$100.75m
MRTXMirati Therapeutics, Inc.
1.65%102.392.3%$88.04m
NBIXNeurocrine Biosciences, Inc.
-1.18%109.605.0%$84.66m

Company Profile

Fate Therapeutics, Inc. operates as a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorder. The firm programme cellular therapeutics for the treatment of life threatening diseases, hematologic malignancies, genetic disorders and diseases resulting from the dysregulation of the immune system. Its products include ProHema, ProTmune, Adaptive NK, iPSC-derived NK, Programmed CD34 and T cell therapy. The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko and John D. Mendlein on April 27, 2007 and is headquartered in San Diego, CA.